Patents matching “oxygen”

US 8404631

Compositions and methods for the delivery of oxygen

The Regents of the University of California · Granted Mar 26, 2013 · Expires Mar 21, 2033

US 8399666

5-lipoxygenase-activating protein (FLAP) inhibitors

Panmira Pharmaceuticals, LLC · Granted Mar 19, 2013 · Expires Mar 14, 2033

US 8008038

Methods for determining oxygen concentration with protoporphyrin IX

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM · Granted Aug 30, 2011 · Expires Aug 25, 2031

US 7919621

Tricyclic inhibitors of 5-lipoxygenase

AMIRA PHARMACEUTICALS, INC. · Granted Apr 5, 2011 · Expires Mar 31, 2031

US 7834037

5-lipoxygenase-activating protein (FLAP) inhibitors

AMIRA PHARMACEUTICALS, INC. · Granted Nov 16, 2010 · Expires Nov 11, 2030

US 7795274

5-lipoxygenase-activating protein (FLAP) inhibitors

AMIRA PHARMACEUTICALS, INC. · Granted Sep 14, 2010 · Expires Sep 9, 2030

US 7405302

5-lipoxygenase-activating protein (FLAP) inhibitors

AMIRA PHARMACEUTICALS, INC. · Granted Jul 29, 2008 · Expires Jul 24, 2028

US 7347987

Inhibition of reactive oxygen species and protection of mammalian cells

The Regents of the University of Oklahoma · Granted Mar 25, 2008 · Expires Mar 20, 2028

US 7329401

Cyclooxygenase-2 selective agents useful as imaging probes and related methods

The Regents of the University of California · Granted Feb 12, 2008 · Expires Feb 7, 2028

US 7241571

Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis

The Regents of the University of California · Granted Jul 10, 2007 · Expires Jul 5, 2027

US 7101846

Methods and compositions for optimization of oxygen transport by cell-free systems

The Regents of the University of California · Granted Sep 5, 2006 · Expires Aug 31, 2026

US 7060733

Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species

The Regents of the University of California · Granted Jun 13, 2006 · Expires Jun 8, 2026

US 6953786

Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof

The Regents of the University of California · Granted Oct 11, 2005 · Expires Oct 6, 2025

US 6916843

Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids

The United States of America, as represented by the Department of Health and Human Services · Granted Jul 12, 2005 · Expires Jul 7, 2025

US 6756399

Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents

The United States of America, as represented by the Department of Health and Human Services · Granted Jun 29, 2004 · Expires Jun 24, 2024

US 6730692

Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Maxim Pharmaceuticals, Inc. · Granted May 4, 2004 · Expires Apr 29, 2024

US 6479546

Allosteric inhibitors of lipoxygenase

The Regents of the University of California · Granted Nov 12, 2002 · Expires Nov 7, 2022

US 6462067

Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Maxim Pharmaceuticals, Inc. · Granted Oct 8, 2002 · Expires Oct 3, 2022

US 6455541

Suppression, by 5-lipoxygenase inhibitors, of bone resorption

The Board of Regents of the University of Texas System · Granted Sep 24, 2002 · Expires Sep 19, 2022

US 6432918

Methods and compositions for optimization of oxygen transport by cell-free systems

The Regents of the University of California · Granted Aug 13, 2002 · Expires Aug 8, 2022

US 6407133

Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Maxim Pharmaceuticals, Inc. · Granted Jun 18, 2002 · Expires Jun 13, 2022

US 6350785

Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors

Maxim Pharmaceuticals, Inc. · Granted Feb 26, 2002 · Expires Feb 21, 2022

US 6270781

Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors

Maxim Pharmaceuticals, Inc. · Granted Aug 7, 2001 · Expires Aug 2, 2021

US 6242473

Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Maxim Pharmaceuticals, Inc. · Granted Jun 5, 2001 · Expires May 31, 2021